-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7

Benzinga·08/13/2026 16:17:09
语音播报
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.